MYM Nutraceuticals Inc. (CSE:MYM) (“MYM”) is pleased to announce the hiring of Joel Lalancette as Master Grower at the company’s 1.5 million square foot medicinal cannabis greenhouse facility, currently under construction in Weedon, Quebec.
Mr. Lalancette brings with him thirteen years of experience in the greenhouse industry. He is an integrated operator who has been a leader in establishing numerous greenhouse businesses. His most recent experience saw him establish himself as one of Quebec’s largest producers of microgreens. Mr. Lalancette has vast knowledge and experience in large-scale greenhouse projects and is an expert in multi-zone, computer-controlled climate systems, hydroponic, aeroponic, and traditional soil systems.
“We are thrilled to welcome Master Grower Joel Lalancette to manage and maintain the upcoming 1.5 million square foot greenhouse project in Weedon, Quebec.” said Rob Gietl, CEO of MYM. “Mr. Lalancette’s many years of greenhouse experience will benefit our operations in Weedon and ensure our high-yield facility runs efficiently and in a cost-effective manner. We are inspired by Joel’s cost saving innovations in the greenhouse industry and rely on his expertise to keep production expenses low and per gram costs at a minimum.”
In addition to managing greenhouse crews and maintaining growing protocols, Mr. Lalancette will be responsible for cloning, transplanting, feeding plants, defoliation, super cropping, topping, flushing, foliar and preventative sprays, trimming, packaging, waste disposal and inventory management. Mr. Lalancette has an
in-depth knowledge of preventative maintenance, temperature and humidity manipulation, plant diseases, and cannabis strains.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a shareholder in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
Keep up to date with MYM on our social media channels:
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.